Post-market follow-up of AnGelHA 2 hyaluronic acid filler for wrinkles and facial contouring
Official title: A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.
Run by Glyance · NCT07495865 · Data updated 2026-11-12
This project will try AnGelHA 2 filler to reduce moderate to severe facial wrinkles and improve facial contours in adults seeking non-surgical aesthetic injections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 87 (estimated) |
| Sponsor | Glyance Industry-sponsored |
| Locations | 1 site (Lod, Israel) |
| Status | Recruiting |
| Started | February 8, 2026 |
| Main results expected | March 12, 2027 |
| Study ends | March 12, 2027 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT07495865 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who want non-surgical injections for moderate to severe facial wrinkles or contouring, can provide informed consent, and do not have contraindications such as pregnancy, recent filler in the target area, or known hypersensitivity are ideal candidates.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have had dermal filler in the prior six months or permanent fillers in the intended area, have active skin infection or inflammation near the treatment site, known allergy to hyaluronic acid or lidocaine, or uncontrolled medical conditions are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-interventional, open-label post-market follow-up of AnGelHA 2 administered in routine clinical practice. Adult participants who receive at least one injection with AnGelHA 2 are enrolled and treated according to the practitioner's usual technique, volume, depth, and retreatment decisions. Safety and performance are tracked with area-specific and whole-face appearance assessments and routine safety monitoring. Follow-up visits are optional and planned at 1, 3, 6, 9, and 12 months after baseline, with additional visits allowed as needed.
Why it matters
Potential benefit: If successful, AnGelHA 2 may offer a safe and effective option to reduce moderate to severe facial wrinkles and improve facial contour using routine non-surgical injections.
How similar studies have gone: Numerous clinical and post-market studies of hyaluronic acid fillers have demonstrated favorable safety and performance for wrinkle correction, so this approach aligns with existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or women of any race, 18 years of age or older. * Able to read, understand and sign informed consent. Exclusion Criteria: * Pregnant or lactating women (contraindications as per IFU). * Having received prior dermal filler injections in the six months preceding the study. * Previously treated with semi-permanent or permanent filler in the intended injection area. * Presenting with a cutaneous disorder, inflammation or infection near to the treatment area. * Known hypersensitivity to lidocaine and/or lidocaine HCl or hyaluronic acid. * Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder. * Undergoing or planning to undergo peeling treatment or laser-/ultrasound-based treatment within 3 weeks before or after injection. * Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed. * Subject, who has a condition or is in Fuse
Where it's running
-
Glyance Ltd
Lod, Israel, Israel Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multi-functional home beauty device for cosmetic skin appearance and texture improvement
This study tests a home-use beauty device, along with a skincare regimen, to see if it improves skin appearance and safety over about 4 weeks in adults aged 30–65.
-
One facial acupuncture session to see if it improves skin and how satisfied people are with their look
A single facial rejuvenation acupuncture session is being tested in adults 30–60 to see if it improves skin structure and how happy people are with their appearance.
-
Perioral rejuvenation with hyaluronic acid to reduce perioral lines and restore lip fullness
This will see if routine perioral rejuvenation injections with hyaluronic acid can increase lip fullness and reduce perioral lines in adults getting aesthetic treatment at a clinic.
-
Hyaluronic acid fillers for lips, cheeks, nasolabial folds, perioral lines, and under-eye hollows in everyday practice
This trial will try hyaluronic acid dermal fillers in adults who want cosmetic treatment of the lips, cheeks, nasolabial folds, perioral lines, or infraorbital hollows to see how long the effects last and to record safety.
-
Topical poly-L-lactic acid with microneedling for perioral wrinkles
This trial will test whether applying topical poly-L-lactic acid with microneedling helps reduce perioral wrinkles in adults aged 40–70.
-
DMFI300 versus Ellansé‑M for nasolabial fold wrinkles
This test will try DMFI300 in adults with moderate-to-severe nasolabial folds to see if it smooths wrinkles as well as or better than Ellansé‑M.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.